By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Precision BioSciences today announced that in a reexamination proceeding the US Patent and Trademark Office has rejected claims by Cellectis that Precision infringed on four of its patents.

The USPTO issued its Final Decisions and Right of Appeal Notices in the reexamination of US Patent Nos. 6,833,252; 7,214,536; 6,610,545; and 7,309,605. The patents are owned by the Institut Pasteur and the Universite Pierre et Marie Curie and licensed to Cellectis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.